Vol 28, No 1 (2021)
Original Article
Published online: 2020-11-09

open access

Page views 2175
Article views/downloads 1876
Get Citation

Connect on Social Media

Connect on Social Media

Low dose of ROSuvastatin in combination with EZEtimibe effectively and permanently reduce low density lipoprotein cholesterol concentration independently of timing of administration (ROSEZE): A randomized, crossover study — preliminary results

Karolina Obońska1, Michał Kasprzak1, Kamila Tymosiak1, Tomasz Fabiszak1, Magdalena Krintus2, Jacek Kubica1
Pubmed: 33200812
Cardiol J 2021;28(1):58-66.


Background: In an attempt to improve low density lipoprotein-cholesterol (LDL-C) level control in patients ineffectively treated with statins, we evaluated the effectiveness of a fixed-dose combination (FDC) of 10 mg rosuvastatin and ezetimibe and its relation to the timing of drug administration.

A randomized, open label, single center, crossover study involving 83 patients with coronary
artery disease and hypercholesterolemia with baseline LDL-C ≥ 70 mg/dL. In arm I the FDC drug was
administered in the morning for 6 weeks, then in the evening for the following 6 weeks and vice versa
in arm II. The primary endpoint was the change in LDL-C after 6 and 12 weeks.

The median LDL-C concentration at baseline, after 6 and 12 weeks respectively was:
98.10 mg/dL (Q1;Q3: 85.10;116.80), 63.14 mg/dL (50.70;77.10) and 59.40 mg/dL (49.00;73.30);
p < 0.001. LDL-C levels were similar regardless of the timing of drug administration (morning 62.50
mg/dL [50.70;76.00] vs. evening 59.70 mg/dL [48.20;73.80]; p = 0.259], in both time points: 6 week:
63.15 mg/dL (50.75;80.65) vs. 63.40 mg/dL (50.60;74.00), p = 0.775; and 12 week: 62.00 mg/dL
(50.20;74.40) vs. 59.05 mg/dL (47.65;66.05), p = 0.362. The absolute change in LDL-C concentration
for the morning vs. evening drug administration was — 6 week: –34.6 mg/dL (–56.55; –19.85)
(–34.87%) vs. –31.10 mg/dL (–44.20; –16.00) (–35.87%) (p not significant); 12. week: –34.20 mg/dL
(–47.8; –19.0) (–37.12%) vs. –37.20 mg/dL (–65.55; –23.85) (–40.06%) (p not significant). The therapy
was safe and well tolerated.

Fixed-dose combination of rosuvastatin and ezetimibe significantly and permanently
decreases LDL-C regardless of the timing of drug administration.

Article available in PDF format

View PDF Download PDF file


  1. Ibanez B, James S, Agewall S, et al. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J. 2018; 39: 119–177.
  2. Townsend N, Nichols M, Scarborough P, et al. Cardiovascular disease in Europe — epidemiological update 2015. Eur Heart J. 2015; 36(40): 2696–2705.
  3. Catapano A, Graham I, Backer GDe, et al. 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias. The Task Force for the Management of Dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS). Developed with the special contribution of the European Assocciation for Cardiovascular Prevention & Rehabilitation (EACPR). Eur Heart J. 2016; 37(39): 2999–3058.
  4. Mach F, Baigent C, Catapano AL, et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020; 41(1): 111–188.
  5. Reiner Ž, De Backer G, Fras Z, et al. Lipid lowering drug therapy in patients with coronary heart disease from 24 European countries — Findings from the EUROASPIRE IV survey. Atherosclerosis. 2016; 246: 243–250.
  6. Ho PM, Bryson CL, Rumsfeld JS. Medication adherence: its importance in cardiovascular outcomes. Circulation. 2009; 119(23): 3028–3035.
  7. Osterberg L, Blaschke T. Adherence to medication. N Engl J Med. 2005; 353(5): 487–497.
  8. Dykun I, Wiefhoff D, Totzeck M, et al. Disconcordance between ESC prevention guidelines and observed lipid profiles in patients with known coronary artery disease. Int J Cardiol Heart Vasc. 2019; 22: 73–77.
  9. Presta V, Figliuzzi I, Miceli F, et al. Achievement of low density lipoprotein (LDL) cholesterol targets in primary and secondary prevention: Analysis of a large real practice database in Italy. Atherosclerosis. 2019; 285: 40–48.
  10. Obońska K, Kasprzak M, Sikora J, et al. The impact of the time of drug administration on the effectiveness of combined treatment of hypercholesterolemia with Rosuvastatin and Ezetimibe (RosEze): study protocol for a randomized controlled trial. Trials. 2017; 18(1): 316.
  11. Baigent C, Blackwell L, Emberson J, et al. Cholesterol Treatment Trialists’ (CTT) Collaboration. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010; 376(9753): 1670–1681.
  12. Silverman MG, Ference BA, Im K, et al. Association between lowering LDL-C and cardiovascular risk reduction among different therapeutic interventions: a systematic review and meta-analysis. JAMA. 2016; 316(12): 1289–1297.
  13. Navarese EP, Robinson JG, Kowalewski M, et al. Association between baseline LDL-C level and total and cardiovascular mortality after LDL-C lowering: a systematic review and meta-analysis. JAMA. 2018; 319(15): 1566–1579.
  14. Mikhailidis DP, Lawson RW, McCormick AL, et al. Comparative efficacy of the addition of ezetimibe to statin vs statin titration in patients with hypercholesterolaemia: systematic review and meta-analysis. Curr Med Res Opin. 2011; 27(6): 1191–1210.
  15. Ambegaonkar BM, Tipping D, Polis AB, et al. Achieving goal lipid levels with ezetimibe plus statin add-on or switch therapy compared with doubling the statin dose. A pooled analysis. Atherosclerosis. 2014; 237(2): 829–837.
  16. Lorenzi M, Ambegaonkar B, Baxter CA, et al. Ezetimibe in high-risk, previously treated statin patients: a systematic review and network meta-analysis of lipid efficacy. Clin Res Cardiol. 2019; 108(5): 487–509.
  17. Cannon CP, Blazing MA, Giugliano RP, et al. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med. 2015; 372(25): 2387–2397.
  18. Bach RG, Cannon CP, Giugliano RP, et al. Effect of simvastatin-ezetimibe compared with simvastatin monotherapy after acute coronary syndrome among patients 75 years or older: a secondary analysis of a randomized clinical trial. JAMA Cardiol. 2019; 4(9): 846–854.
  19. Kato ET, Cannon CP, Blazing MA, et al. Efficacy and safety of adding ezetimibe to statin therapy among women and men: insight from IMPROVE-IT (improved reduction of outcomes: vytorin efficacy international trial). J Am Heart Assoc. 2017; 6(11).
  20. Jones PH, Davidson MH, Stein EA, et al. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial). Am J Cardiol. 2003; 92(2): 152–160.
  21. Schuster H, Barter PJ, Stender S, et al. Effects of switching statins on achievement of lipid goals: measuring effective reductions in cholesterol using rosuvastatin therapy (MERCURY I) study. Am Heart J. 2004; 147(4): 705–713.
  22. Clearfield MB, Amerena J, Bassand JP, et al. Comparison of the efficacy and safety of rosuvastatin 10 mg and atorvastatin 20 mg in high-risk patients with hypercholesterolemia — Prospective study to evaluate the Use of Low doses of the Statins Atorvastatin and Rosuvastatin (PULSAR). Trials. 2006; 7: 35.
  23. Kim KJ, Kim SH, Yoon YW, et al. Effect of fixed-dose combinations of ezetimibe plus rosuvastatin in patients with primary hypercholesterolemia: MRS-ROZE (Multicenter Randomized Study of ROsuvastatin and eZEtimibe). Cardiovasc Ther. 2016; 34(5): 371–382.
  24. Hong SJ, Jeong HS, Ahn JC, et al. A Phase III, Multicenter, Randomized, Double-blind, Active Comparator Clinical Trial to Compare the Efficacy and Safety of Combination Therapy With Ezetimibe and Rosuvastatin Versus Rosuvastatin Monotherapy in Patients With Hypercholesterolemia: I-ROSETTE (Ildong Rosuvastatin & Ezetimibe for Hypercholesterolemia) Randomized Controlled Trial. Clin Ther. 2018; 40(2): 226–241.e4.
  25. Mickiewicz A, Futema M, Ćwiklinska A, et al. Higher responsiveness to rosuvastatin in polygenic versus monogenic hypercholesterolaemia: a propensity score analysis. Life (Basel). 2020; 10(5): 73.
  26. Thanassoulis G, Williams K, Ye K, et al. Relations of change in plasma levels of LDL-C, non-HDL-C and apoB with risk reduction from statin therapy: a meta-analysis of randomized trials. J Am Heart Assoc. 2014; 3(2): e000759.
  27. Pedersen T, Olsson A, Færgeman O, et al. Lipoprotein changes and reduction in the incidence of major coronary heart disease events in the Scandinavian Simvastatin Survival Study (4S). Circulation. 1998; 97(15): 1453–1460.
  28. Jones PH, Hunninghake DB, Ferdinand KC, et al. Effects of rosuvastatin versus atorvastatin, simvastatin, and pravastatin on non-high-density lipoprotein cholesterol, apolipoproteins, and lipid ratios in patients with hypercholesterolemia: additional results from the STELLAR trial. Clin Ther. 2004; 26(9): 1388–1399.
  29. Ahmed O, Littmann K, Gustafsson U, et al. Ezetimibe in combination with simvastatin reduces remnant cholesterol without affecting biliary lipid concentrations in gallstone patients. J Am Heart Assoc. 2018; 7(24): e009876.
  30. Simes RJ, Marschner IC, Hunt D, et al. Relationship between lipid levels and clinical outcomes in the long-term intervention with pravastatin in the ischemic disease (LIPID) trial. To what extent is the reduction in coronary events with pravastatin explained by onstudy lipid levels? Circulation. 2002; 105: 1162–1169.
  31. Nozue T, Michishita I, Mizuguchi I. Effects of ezetimibe on remnant-like particle cholesterol, lipoprotein (a), and oxidized low-density lipoprotein in patients with dyslipidemia. J Atheroscler Thromb. 2010; 17(1): 37–44.
  32. Sahebkar A, Simental-Mendía L, Pirro M, et al. Impact of ezetimibe on plasma lipoprotein(a) concentrations as monotherapy or in combination with statins: a systematic review and meta-analysis of randomized controlled trials [published correction appears in Sci Rep 2020; 10(1): 2999]. Scientific Reports. 2018; 8(1): 17887.
  33. Jones PJ, Schoeller DA. Evidence for diurnal periodicity in human cholesterol synthesis. J Lipid Res. 1990; 31(4): 667–673.
  34. Parker TS, McNamara DJ, Brown C, et al. Mevalonic acid in human plasma: relationship of concentration and circadian rhythm to cholesterol synthesis rates in man. Proc Natl Acad Sci U S A. 1982; 79(9): 3037–3041.
  35. Nishida C, Matsumoto Y, Fujimoto K, et al. The bioequivalence and effect of food on the pharmacokinetics of a fixed-dose combination tablet containing rosuvastatin and ezetimibe in healthy Japanese subjects. Clin Transl Sci. 2019; 12(6): 704–712.
  36. Ren Y, Zhu H, Fan Z, et al. Comparison of the effect of rosuvastatin versus rosuvastatin/ezetimibe on markers of inflammation in patients with acute myocardial infarction. Exp Ther Med. 2017; 14(5): 4942–4950.
  37. Bohula EA, Giugliano RP, Cannon CP, et al. Achievement of dual low-density lipoprotein cholesterol and high-sensitivity C-reactive protein targets more frequent with the addition of ezetimibe to simvastatin and associated with better outcomes in IMPROVE-IT. Circulation. 2015; 132(13): 1224–1233.
  38. Vavlukis M, Vavlukis A. Adding ezetimibe to statin therapy: latest evidence and clinical implications. Drugs Context. 2018; 7: 212534.